Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

2.

Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.

Keizman D, Sarid D, Lee JL, Sella A, Gottfried M, Hammers H, Eisenberger MA, Carducci MA, Sinibaldi V, Neiman V, Rosenbaum E, Peer A, Neumann A, Mermershtain W, Rouvinov K, Berger R, Yildiz I.

Oncologist. 2016 Oct;21(10):1212-1217. Epub 2016 Jul 5.

3.

Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.

Keizman D, Ish-Shalom M, Sella A, Gottfried M, Maimon N, Peer A, Hammers H, Eisenberger MA, Sinibaldi V, Neiman V, Rosenbaum E, Sarid D, Mermershtain W, Rouvinov K, Berger R, Carducci MA.

Clin Genitourin Cancer. 2016 Oct;14(5):420-425. doi: 10.1016/j.clgc.2016.04.012. Epub 2016 Apr 27.

PMID:
27211307
4.

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA.

Prostate. 2016 Apr;76(5):512-20. doi: 10.1002/pros.23141. Epub 2015 Dec 22.

PMID:
26689606
5.

Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?

Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, Eisenberger MA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, Weitzen R, Berger R.

Cancer Res Treat. 2016 Jan;48(1):281-7. doi: 10.4143/crt.2014.289. Epub 2015 Mar 5.

6.

American Cancer Society prostate cancer survivorship care guidelines.

Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W 3rd, Salner AL, Zelefsky MJ, Aragon-Ching JB, Slovin SF, Wittmann DA, Hoyt MA, Sinibaldi VJ, Chodak G, Pratt-Chapman ML, Cowens-Alvarado RL.

CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49. doi: 10.3322/caac.21234. Epub 2014 Jun 10. Erratum in: CA Cancer J Clin. 2014 Nov-Dec;64(6):445.

7.

Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.

Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D.

Prostate. 2014 Apr;74(4):433-40. doi: 10.1002/pros.22765. Epub 2013 Dec 11.

8.

Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.

Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA.

Oncologist. 2014 Jan;19(1):51-60. doi: 10.1634/theoncologist.2012-0335. Epub 2013 Dec 5.

9.

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.

Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A.

Oncologist. 2012;17(12):1508-14. doi: 10.1634/theoncologist.2012-0125. Epub 2012 Sep 12.

10.

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA.

Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10.

PMID:
22409947
11.

The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.

Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Walczak J, Eisenberger MA.

Prostate. 2011 Nov;71(15):1608-15. doi: 10.1002/pros.21377. Epub 2011 Mar 22.

12.

[Acute abdomen in renal transplant recipients. Epidemiology and treatment in not referral transplantation centers].

Costa G, Tierno SM, Stella F, Tomassini F, Venturini L, Frezza B, Fazzari L, Sinibaldi V, De Marco CM, Cancrini G, Regine G.

G Chir. 2010 Nov-Dec;31(11-12):497-501. Italian.

PMID:
21232191
13.

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M.

Clin Cancer Res. 2010 Nov 1;16(21):5269-76. doi: 10.1158/1078-0432.CCR-10-1928. Epub 2010 Oct 26.

14.

Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.

Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, Deweese T, Eisenberger MA.

Urol Oncol. 2011 Nov-Dec;29(6):670-5. doi: 10.1016/j.urolonc.2009.10.003. Epub 2009 Dec 4.

15.

TNF-blockade in patients with advanced hormone refractory prostate cancer.

Diaz LA Jr, Messersmith W, Sokoll L, Sinibaldi V, Moore S, Carducci M, Eisenberger M.

Invest New Drugs. 2011 Feb;29(1):192-4. doi: 10.1007/s10637-009-9346-1. Epub 2009 Oct 21. No abstract available.

16.
17.

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.

Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR.

Cancer Biol Ther. 2007 Sep;6(9):1360-7. Epub 2007 Jun 5.

18.

Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.

Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL.

Urology. 2007 Mar;69(3):526-31.

PMID:
17382158
19.

The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later.

Eisenberger MA, Sinibaldi VW.

Oncology (Williston Park). 2006 Jul;20(8):853-62; discussion 863, 867-8. Review.

20.

Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.

Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA.

Am J Clin Oncol. 2006 Aug;29(4):395-8.

PMID:
16891869
21.

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.

Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA.

Clin Cancer Res. 2005 Jun 15;11(12):4437-43.

22.

A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.

Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA.

J Interferon Cytokine Res. 2004 Jan;24(1):37-41.

PMID:
14980083
23.

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.

Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D.

Urology. 2004 Jan;63(1):114-9.

PMID:
14751361
24.

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.

Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ.

J Clin Oncol. 2002 Apr 15;20(8):2171-80. Erratum in: J Clin Oncol. 2003 Jun 15;21(12):2449.

PMID:
11956279
25.

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.

Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.

Cancer. 2002 Mar 1;94(5):1457-65.

26.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC.

Clin Cancer Res. 2001 Oct;7(10):3047-55.

27.

Clinical conduct and nursing quality of life in prostate cancer.

Sinibaldi VJ, Arzoomanian RZ.

Hematol Oncol Clin North Am. 2001 Jun;15(3):573-81. Review.

PMID:
11525298
28.

Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.

Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA.

Urology. 1999 Oct;54(4):745.

PMID:
10754148
29.

Complete androgen blockade for prostate cancer: what went wrong?

Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA.

J Urol. 2000 Jul;164(1):3-9. Review.

PMID:
10840412
30.
31.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al.

J Clin Oncol. 1999 Nov;17(11):3461-7. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702. J Clin Oncol 2000 Jul;18(13):2644. J Clin Oncol. 2007 Mar 20;25(9):1154.

PMID:
10550143
32.

Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.

Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ.

Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):631-4.

33.

A prospective study of suramin-induced peripheral neuropathy.

Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR.

Brain. 1996 Dec;119 ( Pt 6):2039-52.

PMID:
9010008
34.

Prostate cancer treatment strategies based on tumor-specific biological principles: future directions.

Carducci MA, DeWeese TL, Nelson WG, Simons JW, Sinibaldi V, Eisenberger MA.

Semin Oncol. 1996 Dec;23(6 Suppl 14):56-62. Review.

PMID:
8996587
35.

Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.

Hemady RK, Sinibaldi VJ, Eisenberger MA.

Am J Ophthalmol. 1996 Mar;121(3):291-6.

PMID:
8597272
36.

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ.

J Clin Oncol. 1995 Dec;13(12):2944-53.

PMID:
8523059
37.

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.

Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R.

J Clin Oncol. 1995 Sep;13(9):2187-95.

PMID:
7666077
38.

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.

Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC, et al.

J Clin Oncol. 1995 Sep;13(9):2174-86.

PMID:
7666076
39.

Suramin.

Eisenberger MA, Sinibaldi V, Reyno L.

Cancer Pract. 1995 May-Jun;3(3):187-9. Review. No abstract available.

PMID:
7599677
40.

Combined carboplatin plus bleomycin and conventional radiotherapy for advanced carcinomas of the head and neck.

Espinoza-Jacobs MC, Suntharalingam M, Eisenberger M, Sinibaldi V, Salazar OM.

Am J Clin Oncol. 1995 Feb;18(1):52-5.

PMID:
7531390
41.

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.

Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ.

J Clin Oncol. 1994 Jan;12(1):166-75.

PMID:
8270974
42.

Suramin, an active drug for prostate cancer: interim observations in a phase I trial.

Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC, Egorin MJ.

J Natl Cancer Inst. 1993 Apr 21;85(8):611-21. Erratum in: J Natl Cancer Inst 1994 Apr 20;86(8):639-40.

PMID:
8468719
43.

Suramin interferes with measurements of total calcium and serum amylase by the Kodak Ektachem 700 analyzer and may inhibit liver enzyme activity.

Gregory LC, Eisenberger M, Sinibaldi V, Koch TR.

Clin Chem. 1992 Dec;38(12):2552-3. No abstract available.

44.

Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck.

Kruter F, Eisenberger M, Sinibaldi V, Engstrom C, Jacobs M, Abrams J, Belani C, Gray W, Krasnow S.

Invest New Drugs. 1992 Jul;10(2):89-91.

PMID:
1500270
45.

Carboplatin in the treatment of squamous cell head and neck cancers.

Aisner J, Sinibaldi V, Eisenberger M.

Semin Oncol. 1992 Feb;19(1 Suppl 2):60-5. Review.

PMID:
1411628
46.

Approaches to optimal dosing of hexamethylene bisacetamide.

Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA.

Cancer Chemother Pharmacol. 1992;31(1):37-45.

PMID:
1333894
47.

Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.

Conley BA, Egorin MJ, Sinibaldi V, Van Echo DA.

Invest New Drugs. 1990 Nov;8(4):365-7. No abstract available.

PMID:
2150671
48.

A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.

Eisenberger M, Krasnow S, Ellenberg S, Silva H, Abrams J, Sinibaldi V, Van Echo D, Aisner J.

J Clin Oncol. 1989 Sep;7(9):1341-5.

PMID:
2671289
49.

Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: a phase I-II study.

Jacobs MC, Eisenberger M, Oh MC, Sinibaldi V, Gray W, Elias G, Salazar OM.

Int J Radiat Oncol Biol Phys. 1989 Aug;17(2):361-3.

PMID:
2666366
50.

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA.

Cancer Res. 1989 Jun 15;49(12):3436-40.

Supplemental Content

Loading ...
Support Center